Eribulin in mTNBC Patients

Fudan University

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT04541420

YOUNGBC-12

Details and patient eligibility

About

To evaluate the efficacy and safety of Eribulin in patients with advanced breast cancer.

Enrollment: 208 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
2. Eribulin treatment of advanced breast cancer for at least one cycle, between Dec 2019 and Aug 2020.
3. Available medical history.

Exclusion criteria

1. Incomplete medical history.

Trial design

208 participants in 1 patient group

Eribulin

Description:

Eribulin 1.4mg/m2 d1,8 iv q3w